Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.

摘要: Glioblastoma multiforme (GBM) is the most common and aggressive glial cell-derived primary tumor. Current standard of care for patients with GBM includes maximal tumor resection plus adjuvant radiotherapy temozolomide chemotherapy, increasing median overall survival to a mere 15 months from diagnosis. Because these therapies are inherently nonspecific, there an increased likelihood off-target incomplete effects; therefore, targeted modalities required enhanced safety efficacy. Rindopepimut emerging as safe potentially effective drug treatment GBM. consists 14-mer peptide that spans length EGF receptor variant III, mutant found on approximately 30% GBM, conjugated carrier protein keyhole limpet hemocyanin. Vaccination rindopepimut has been shown specifically eliminate cells expressing III. Phase II clinical trials have suggested vaccination newly diagnosed granulocyte-macrophage colony-stimulating factor results in prolonged progression-free minimal toxicity. This review will outline development rindopepimut, well current status this vaccine.